ORUKA THERAPEUTICS

Corporate Overview

NASDAQ: ORKA

January 2026

Disclaimers

The information contained in this presentation has been prepared by Oruka Therapeutics, Inc. (the "Company") and contains information pertaining to the business and operations of the Company. The information contained in this presentation: (a) is provided as at the date hereof, is subject to change without notice, and is based on publicly available information, internally developed data as well as third party information from other sources; (b) does not purport to contain all the information that may be necessary or desirable to fully and accurately evaluate an investment in the Company; (c) is not to be considered as a recommendation by the Company that any person make an investment in the Company; (d) is for information purposes only and shall not constitute an offer to buy, sell, issue or subscribe for, or the solicitation of an offer to buy, sell or issue, or subscribe for any securities of the Company in any jurisdiction in which such offer, solicitation or sale would be unlawful. Where any opinion or belief is expressed in this presentation, it is based on certain assumptions and limitations and is an expression of present opinion or belief only. This presentation should not be construed as legal, financial or tax advice to any individual, as each individual's circumstances are different. This document is for informational purposes only and should not be considered a solicitation or recommendation to purchase, sell or hold a security.

Forward-Looking Information

Certain information set forth in this presentation contains "forward-looking statements" within the meaning of applicable United States securities legislation. Except for statements of historical fact, certain information contained herein constitutes forward-looking statements, which include but are not limited to statements regarding: expectations regarding the efficacy, durability of effect, dosing interval and safety of our product candidates; expectations regarding our plans for clinical trials and research and development programs, including the timing of clinical trials and data readouts; the time periods over which the Company's capital resources will be sufficient to fund its anticipated operations; the Company's business strategy objectives and goals; and management's assessment of future plans and operations, which are based on current internal expectations, estimates, projections, assumptions and beliefs, which may prove to be incorrect. Forward-looking statements are neither historical facts nor assurances of future performance. Forward-looking statements are based on a number of factors and assumptions made by management and considered reasonable at the time such information is provided, and forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements including those uncertainties and factors described under the heading "Risk Factors" and "Cautionary Note Regarding Forward-Looking Statements" in the Company's most recent filings with the SEC, including its Annual Report on Form 10-K, its Quarterly Reports on Form 10-Q and its other filings with the SEC, as well as discussions of potential risks, uncertainties by the Company from time to time, as well as risk factors associated with companies that operate in the biopharma industry, including those associated with the uncertainties of drug development. All of the forward-looking statements made in this presentation are qualified by these cautionary statements and other cautionary statements or other factors contained herein. Although management believes that the expectations conveyed by forward-looking statements herein are reasonable based on information available on the date such forward-looking statements are made, there can be no assurance that forward looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. The forward-looking statements contained herein are presented for the purposes of assisting readers in understanding the Company's plans, objectives and goals and may not be appropriate for other purposes. The reader is cautioned not to place undue reliance on forward-looking statements.

Industry Information

This presentation also contains or references certain industry data that is based upon information from independent industry publications, market research, and surveys and other publicly available sources. Although the Company believes these sources to be generally reliable, such information is subject to interpretation and cannot be verified with complete certainty due to limits on the availability and reliability of data, the voluntary nature of the data gathering process and other inherent limitations and uncertainties. The Company has not independently verified any of the data from third party sources referred to in this presentation and accordingly, the Company makes no representation or warranty as to the origin, validity, accuracy, completeness, currency or reliability of the information in this presentation.

On a mission to enable freedom from chronic skin disease

Our goal

Help patients with chronic skin conditions experience the **greatest possible freedom from disease**

Highest possible rates of disease clearance

+

Fewest number of doses

Our pipeline



Notes: Oruka has exclusive worldwide rights to ORKA-001 (for all fields outside of IBD) and ORKA-002 (for all fields) from Paragon Therapeutics
Abbreviations: HS, hidradenitis suppurativa; PsA, psoriatic arthritis; PsO, psoriasis

Bimzelx launch shows that better biologics will win in psoriasis

Bimzelx versus Sotyktu performance validates our thesis



- **UCB's Bimzelx launch has exceeded expectations, driven by strong demand –** ~$2B annualized 2025 sales, with $5B+ peak sales consensus
- **Market underestimated the opportunity –** UCB market cap ~$15B pre-launch vs. ~$50B two years later (>$30B market cap created on Bimzelx alone)
- **Strong launch driven by PsO in U.S. –** proof point that smaller, non-incumbent company can effectively commercialize in PsO

- **Sotyktu underperformed due to lack of demand –** sub-optimal efficacy with JAK-like safety overhang
- **Market access dynamics not meaningfully different from Bimzelx –** not a major driver

Notes & Sources: (1) Jefferies (based on IQVIA data), shown as 2-week moving average

The psoriasis market will continue to reward biologic innovation

Massive market size

$30B+

Growing moderate-to-severe psoriasis market, with further potential in mild-to-moderate disease

Continued pharma investment

Takeda — nimbus THERAPEUTICS

Lilly — DICE Therapeutics

J&J — Protagonist Therapeutics

Pharma has bet big on orals, sacrificing efficacy for perceived convenience

Better biologics continue to win

$5B+ Bimzelx® (bimekizumab-bkzx)

peak sales forecast

Bimzelx launch shows non-incumbents can achieve access if they have a drug physicians want

ORKA-001 & -002 complement each other to address all PsO/PsA

ORKA-001

For patients with purely skin disease



Majority of dermatologists prefer an anti-IL-23p19

ORKA-002

For patients with joint involvement, including PsA, or recalcitrant skin disease



Anti-IL-17 preferred, and **IL-17A/F emerging as the best approach**

ORKA-021

Sequential **combination of -002 and -001 –** rapid response with ideal maintenance profile

Creates **another way to "win"** in defining the best possible regimen in PsO and PsA

1-2 doses per year is enough to win, but we are aiming far higher



Greater efficacy

KNOCKOUT demonstrates potential for highest ever efficacy from higher IL-23 antibody exposure

Off-treatment remission

High anti-IL-23 exposures could lead to immune reset and long-lasting disease clearance in some patients

IL-17 to IL-23 combination

ORKA-021 could deliver rapid and deep responses with an ideal maintenance profile

Maximizes odds of having a strong value proposition to achieve preferred access and price for innovation

Advancing co-leads rapidly towards multiple clinical data catalysts



Strong cash position provides runway >1 year beyond three major readouts:
EVERLAST-A Ph2a in 2H 2026, EVERLAST-B Ph2b in 2027, and ORCA-SURGE Ph2 in 2027

ORUKA THERAPEUTICS

ORKA-001: potentially best-in-class anti-IL-23p19

ORUKA THERAPEUTICS

Biologics have raised the bar on standard of care in PsO, but there is ample room for improvement



Notes & Sources: FDA Approval Labels and publications of Phase 3 trials supporting approval; W16 PASI 100 not reported for Ilumya (W12 data shown), Otezla (W16 data shown from comparator arm in Sotyktu label), or Stelara (W16 data shown from comparator arm in Skyrizi UltIMMa-1/2 trials)

ORKA-001 targets validated biology with significantly extended PK

ORKA-001 could be the last word in IL-23p19 inhibitors



Binds a nearly identical epitope to risankizumab



Comparable potency to risankizumab across a variety of assays



ORKA-001 is designed to match the validated biology of Skyrizi (risankizumab), but with a dramatically extended half-life

ORUKA THERAPEUTICS

ORKA-001 Phase 1 results set the stage for a step-change in PsO

Phase 1 results

- Half-life of ~100 days
- C_{max} and AUC that enable "KNOCKOUT" exposures
- PD biomarkers linking antibody PK to target engagement
- Safety and tolerability consistent with the IL-23 class

Three major "ways to win"

Annual dosing	**Once per year dosing,** with a Q6M option if needed for hard-to-treat patients
Best-in-class efficacy	**"KNOCKOUT"** antibody exposures could lead to **highest anti-IL-23 efficacy**
Off-treatment remission	**Multi-year off-treatment remissions** for some patients – **a first in PsO** and a potential paradigm change

Ongoing EVERLAST-A Phase 2a trial in PsO will validate this potential – efficacy data expected in 2H 2026

ORUKA THERAPEUTICS

ORKA-001's 100-day half-life and high AUC derisks upside case

Pharmacokinetic profile of a single subcutaneous dose of ORKA-001



- **~100-day half-life** in humans, >3x longer than risankizumab
- C_{max} exceeds risankizumab's at an equivalent dose[1], suggesting ORKA-001 has **high bioavailability**
- High AUC confirms ability to achieve **exposures matching or exceeding KNOCKOUT**
- Individual PK profiles **show no indication of ADAs**

Notes & Sources: Mean ± SD (N=6 per group). Data cut as of August 6, 2025. (1) Single 300 mg subcutaneous dose of risankizumab in n=6 white healthy volunteers reported in Skyrizi BLA Multi-disciplinary Review and 2019 Khatri (J Clin Pharmacol)

ORKA-001 demonstrated deep and sustained inhibition of STAT3 signaling, a downstream marker of IL-23 activity, through 24 weeks

ORKA-001 from serum inhibits STAT3 phosphorylation following *ex vivo* IL-23 stimulation



Notes: Mean ± SD (N=6 per group). 24 weeks is the longest follow-up available as of the data cut on August 6, 2025.
ORKA-001 (600 mg) data slightly offset for visualization

EVERLAST-A Phase 2a – a potential game changer in PsO

EVERLAST-A Phase 2a proof-of-concept trial in moderate-to-severe psoriasis (NCT07090330)



Initial data in 2H 2026 has potential to deliver on all "upside" scenarios:

- **Definitive test of higher efficacy at higher exposures:** PASI 100 at W16, W28, and beyond
- **Evidence for annual dosing and off-treatment remissions** from durability in "no dose" cohort

Notes: (1) Patients in PASI <100 at Week 28 do not undergo randomization and instead receive ORKA-001 300 mg Q6M
Abbreviations: OLE, open-label extension

EVERLAST-B Phase 2b – initiated in December 2025

EVERLAST-B Phase 2b dose-ranging trial in moderate-to-severe psoriasis (NCT07290569)



- **Dose-ranging trial to enable Phase 3**
- **Rapid enrollment facilitated** by rolling some EVERLAST-A sites to EVERLAST-B
- **Data expected in 2027**

Notes: (1) Expected to be sub-optimal and included for dose-ranging purposes; (2) Patients in PASI <100 at Week 28 do not undergo randomization and instead receive ORKA-001 300 mg Q6M; (3) Initial maintenance dose of ORKA-001 600 mg Q12M administered at Week 52

Phase 2 psoriasis data is robust and predictive of Phase 3

Consistent Phase 2 to 3 translation

Phase 2 PASI 100 rates strongly correlate with Phase 3 at both Week 16 and 28





Low placebo rates

0-2% PASI 100 placebo rate



Facilitates rapid FIH to BLA/NDA timeline (e.g., 6 years for Skyrizi and 6.1 years for Sotyktu)

Notes & Sources: (left) Shown for closest dose from Phase 2 to Phase 3; Phase 2: weighted average of highest doses for Skyrizi and Tremfya used to approximate Phase 3 dose, Bimzelx data estimated from BE ABLE 1 and 2, Taltz Phase 2 only ran to W20; Phase 3: weighted average of pivotal trials for Skyrizi (N=2), Bimzelx (N=3 W16, N=2 W28), Tremfya (N=2), Taltz (N=3). (right) Placebo data at primary endpoint (W12 or W16) from N=31 trials

EVERLAST-A provides multiple “ways to win”

Provide definitive test of higher efficacy at higher exposures

PASI 100 data at Week 16, Week 28, and beyond

Establish evidence for annual dosing and lock in Q6M

Open-ended cohort will validate annual dosing; Q6M dosing arm to show response maintenance

Show compelling signs of off-treatment remissions[1]

Kaplan-Meier curve of PASI 100 durability after induction, with some patients out to ~1 year

Durability data will mature in open label portion creating opportunities for future data releases

Notes & Sources: (1) Defined in the literature as clear skin for a period of 1 year or more after the completion of the last dose of a prescription therapy for psoriasis (2020 Armstrong in BJD)

ORKA-001 PK profile could enable higher efficacy in PsO

KNOCKOUT study testing 2-4x the approved Skyrizi dose showed the highest anti-IL-23 efficacy to date



Skyrizi exposure-response model indicates potential to increase efficacy with higher exposure



Higher efficacy observed with higher anti-IL-23 exposure, with separation increasing from W16 to W28 as efficacy reaches peak

Notes & Sources: (left) Cross-trial comparison of pooled data from KNOCKOUT (N=18) and UltIMMa-1/2 (N=598) from 2025 Blauvelt (Nat Commun) and 2018 Gordon (Lancet). (right) Adapted from 2019 Khatri (Clin Pharmacol Ther) and Skyrizi BLA MDR (Fig. 20); gray line shows model-estimated probabilities for PASI 100 for all patients, including Asian ethnicity; KNOCKOUT exposures estimated from population pharmacokinetic model for Skyrizi

100-day half-life brings once annual dosing within reach

ORKA-001 projected steady-state exposures significantly exceed Skyrizi and make annual dosing likely



Skyrizi C_{max} in UC (median ± 5th and 95th percentiles) supports safety of high anti-IL-23 exposures

Maintenance dosing	Steady-state C_{trough} (µg/mL)
ORKA-001: 300 mg Q6M	>10
ORKA-001: 600 mg Q12M	>5
Skyrizi: 150 mg Q12W (approved PsO regimen)	1.5

Notes & Sources: Oruka modeling based on internal data and published population pharmacokinetic model for Skyrizi; error bars reflect 5th and 95th percentiles. Skyrizi exposures in ulcerative colitis from 2024 Thrake (Clin Pharmacol Ther). Steady-state C_{trough} reflects projected values from PK model for ORKA-001 and observed value from Phase 3 trials for Skyrizi in BLA MDR

“KNOCKOUT” IL-23 inhibition could generate off-treatment remissions by depleting pathogenic TRMs

Robust inhibition of IL-23 could create an “immune reset” in PsO



IL-23 drives differentiation of naive T cells into proinflammatory T cells and TRMs

IL-23 maintains TRMs, which react to external triggers to cause PsO recurrence

Inhibition of IL-23 can normalize TRMs in the skin, which could lead to long-term disease control

High anti-IL-23 exposures deplete pathogenic TRMs in the skin



Sources: (left) Figure modified from 2024 Schakel (poster at EADV); (right) 2025 Blauvelt (Nat Commun)
Abbreviations: TRM, tissue resident memory T cell

EVERLAST could enable compelling rates of “off-treatment remission” for the first time in psoriasis

ORKA-001 could affect the disease biology in a unique way due to optimized exposure and PK…

…potentially resulting in longer-term responses that exceed those seen with prior IL-23 inhibitors

	Dose	Half-life
EVERLAST-A	600 mg	~100d
KNOCKOUT	300-600 mg	28d
Risankizumab	150 mg	28d
Guselkumab	100 mg	17d
Mirikizumab	250 mg	9d



Sources: 2025 Blauvelt (Nat Commun); 2020 Blauvelt (JAMA Dermatol); 2017 Reich (JAAD); 2022 Blauvelt (Br J Dermatol); FDA Labels

Looking forward to a potential label – illustrating the paradigm-changing potential of ORKA-001

Induction

Induction with ORKA-001 at a dose level selected based on EVERLAST studies

Maintenance

Evaluate at 6 and 12 months after induction dosing to inform whether to give ORKA-001 on one of the following regimens:

- Every 6 months
- Every 12 months
- For patients in remission, i.e., clear skin beyond 12 months, initiate maintenance dosing only if disease recurs

Treatment upon recurrence

Administer ORKA-001 as a subcutaneous injection on recurrence based on clinical evaluation using a dosing regimen of either every 6 or 12 months

ORUKA THERAPEUTICS

Dermatologists value both extended dosing and higher efficacy

Dermatologists say that annual dosing and higher efficacy would drive similar 50%+ share for ORKA-001, even when accounting for entry of icotrokinra



Sources: Survey of N=22 practicing dermatologists

ORKA-002:
potentially best-in-class anti-IL-17A/F

ORUKA THERAPEUTICS

ORKA-002 targets IL-17A/F, a new mega-blockbuster class with an ideal setup for a longer-acting entrant

- **Brand new class –** superior efficacy vs. IL-17A[1] across multiple indications and high levels of skin clearance in IL-17A non-responders[2]
- **Long timeline to biosimilars –** Bimzelx recently approved, and only one other IL-17A/F antibody (sonelokimab) in clinical development
- **Very strong launch –** Bimzelx peak sales estimate now exceeds $5B[3]; strong formulary positioning achieved soon after approval
- **Pipeline-in-a-product expansion potential –** PsA, HS, axSpA, and others

Bimzelx launch validates both the IL-17A/F class and ability to differentiate in PsO



Notes: (1) 2021 Reich (NEJM); (2) 2023 Kokolakis (BJD); (3) Visible Alpha; (4) Jefferies (based on IQVIA data), shown as 2-week moving average
Abbreviations: axSpA, axial spondyloarthritis; HS, hidradenitis suppurativa; PsA, psoriatic arthritis

ORKA-002 matches Bimzelx's IL-17A/F potency with extended PK

ORKA-002 binds a nearly identical epitope to bimekizumab



ORKA-002 has comparable potency to bimekizumab across a variety of assays



ORKA-002 is designed to match the validated biology of Bimzelx (bimekizumab), but with a dramatically extended half-life

Notes: Presented at AAD 2025. (1) Similar epitope for IL-17F as well

ORKA-002 Phase 1 trial design

Phase 1 trial to evaluate the safety, tolerability, and PK of ORKA-002 in healthy participants (NCT06944379)

Design

- Double-blind and placebo-controlled
- Single ascending dose

Population

- Healthy adult volunteers
- N=8 per cohort (6:2 active:placebo)

Endpoints

- Primary: Safety and tolerability
- Secondary: Pharmacokinetics
- Exploratory: Pharmacodynamic markers

Dose levels and length of follow-up to date

Notes: Data cut as of January 6, 2026
Abbreviations: SC, subcutaneous

ORKA-002 safety profile was consistent with the IL-17 class

ORKA-001 and placebo (blinded)	160 mg	320 mg	640 mg	All cohorts
N	8	8	8	24
≥1 TEAE	8 (100%)	8 (100%)	7 (87.5%)	23 (95.8%)
≥1 SAE	0%	0%	0%	0%
≥1 severe TEAE	0%	0%	0%	0%
Discontinued due to TEAE	0%	0%	0%	0%

Only AEs occurring in >2 subjects were contusion[1], headache, skin abrasion[1], and upper respiratory tract infection

ORUKA THERAPEUTICS

Notes: Data cut as of January 6, 2026
(1) Not at the injection site

Half-life of 75-80 days enables potential for twice-yearly dosing

Pharmacokinetic profile of a single subcutaneous dose of ORKA-002



- **$t_{1/2}$ of 75-80 days** in humans, >3x longer than bimekizumab
- **C_{max} comparable to bimekizumab** at an equivalent dose
- Less than dose-proportional exposure in 320 mg group due to higher body weight
- Individual PK profiles **show no indication of ADAs**

Notes: Mean ± SD (N=6 per group). Data cut as of January 6, 2026

ORKA-002 demonstrated deep and sustained inhibition of IL-17 signaling in an *ex vivo* IL-17 stimulation assay through 24 weeks

ORKA-002 from serum inhibits IL-17 signaling following *ex vivo* IL-17 stimulation



Notes: Mean ± SD (N=6 per group). 24 weeks is the longest follow-up available as of the data cut on January 6, 2026

Potential for Q6M dosing in PsO and Q3M dosing in HS

Projected C_{trough} of ORKA-002 exceeds approved bimekizumab regimens in PsO and HS





— **ORKA-002:** 320 mg W0, 4 then Q6M

— **Bimekizumab:** 320 mg W0, 4, 8, 12, 16 then Q8W

— **ORKA-002[1]:** 320 mg W0, 4, 8, 12 then Q3M

— **Bimekizumab:** 320 mg W0, 2, 4, 6, 8, 10, 12, 14, 16 then Q4W

Notes & Sources: Oruka modeling based on internal data and published population pharmacokinetic model and PK parameters for bimekizumab; error bars reflect 5th and 95th percentiles; (1) Assumes similar increase in clearance and volume of distribution in HS as observed with bimekizumab

ORCA-SURGE – initiation expected 1H 2026

ORCA-SURGE Phase 2 dose-ranging trial of ORKA-002 in moderate-to-severe psoriasis



- **ORCA-SURGE data expected in 2027**
- **Phase 2 trial in hidradenitis suppurativa (HS) to start in 2H 2026**

Notes: (1) Expected to be sub-optimal and included for dose-ranging purposes; (2) Placebo patients will receive ORKA-002 at Week 16

ORKA-021: Potential to combine the best of IL-17s and IL-23s

IL-17s: fastest onset and highest peak response + **IL-23s: less frequent dosing and best durability and safety**

Combining the two mechanisms sequentially could provide the "best of both worlds"



Possible with ORKA-021:
ORKA-002 → ORKA-001

Bimzelx® (bimekizumab-bkzx)

Skyrizi® risankizumab-rzaa

Feedback from U.S. dermatologists:

*"It really sounds like a **great option**"*

*"**Conceptually beautiful**"*

*"The only reason this hasn't been done is that **no company has both**"*

Sources: Long-term efficacy from BE BRIGHT (Bimzelx) and LIMMitless (Skyrizi) open-label extension trials

Four ways to deliver a best-in-class regimen for psoriatic disease

- **Once yearly dosing** and **off-treatment remissions** go beyond convenience to **change the treatment paradigm**


ORKA-001

- Clinical precedent supports potential for **best efficacy** in the IL-23 class


ORKA-001

- Only long-acting IL-17A/F in a **brand-new, mega-blockbuster class** with **a long timeline to biosimilars** and **indication expansion potential**


ORKA-002

- Straightforward path to a potential H2H win – **faster and deeper responses** vs. Skyrizi and **superior maintenance profile** vs. Bimzelx


ORKA-021

ORUKA THERAPEUTICS

Multiple Phase 2 readouts coming over the next two years

ORKA-001	EVERLAST-A	*Phase 2a (PsO)*	**2H 2026:** PASI 100 rates and response duration
	EVERLAST-B	*Phase 2b (PsO)*	**2027:** Week 16 and durability
ORKA-002	ORCA SURGE	*Phase 2 (PsO)*	**1H 2026:** Initiation **2027:** Week 16 and durability
	Phase 2 (HS)		**2H 2026:** Initiation

Strong cash position provides runway >1 year beyond three major readouts: EVERLAST-A, EVERLAST-B, and ORCA-SURGE


ORUKA
THERAPEUTICS

Shares outstanding

As of September 30, 2025		Number of shares[1]
Common stock	• Shares outstanding	48.4M
Common stock equivalents	• Preferred stock (as-converted to common stock)	11.4M
	• Pre-funded warrants	7.3M
Common stock and common stock equivalents	• **Total outstanding[2]**	**67.1M**

Notes: Please refer to SEC filings for additional information. (1) Shown on an as-converted-to-common basis; (2) Excludes stock options and warrants held by employees, directors, and service providers